

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (canceled).

17. (currently amended) A method of treating ~~a disease or disorder ameliorated by the inhibition of PDE4 in a patient~~ asthma, inflammation, inflammatory skin disease, psoriasis, atopic dermatitis, contact dermatitis, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, inflammatory bowel disease, Crohn's Disease, chronic bronchitis, allergic rhinitis, arthritis, joint inflammation, inflammation of the eye, allergic responses in the eye, gouty arthritis, arthritic condition, adult respiratory distress syndrome, acute respiratory distress syndrome, reperfusion injury, graft vs host reaction, allograft rejection, systemic lupus erythematosus, leukemia, or neurogenic inflammatory disease associated with irritation or pain, which comprises administering to a patient ~~in need of such treatment~~ a therapeutically effective amount of enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof, wherein the compound inhibits PDE4.

18-23. (canceled).

24. (currently amended) The method of ~~any one of claims 17 to 19~~ claim 17 further comprising administering to a patient ~~in need of such treatment, or control~~ a therapeutically effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti-inflammatory drug, steroid, anti-cancer agent, hematopoietic growth factor, cytokine, stem cell transplantation, or kinase inhibitor.

25. (previously presented) The method of claim 17 wherein the disease or disorder is respiratory disease, asthma, allergic rhinitis, inflammation or chronic pulmonary

inflammatory disease.

26. (previously presented) The method of claim 17 wherein the disease or disorder is chronic obstructive pulmonary disease.

27. (currently amended) The method of claim 17 ~~or 19~~ wherein the patient is a mammal.

28. (currently amended) The method of ~~any one of claims 17 to 19~~ claim 17 wherein the enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, topically, or orally.

29. (currently amended) The method of ~~any one of claims 17 to 19~~ claim 17 wherein the therapeutically effective amount is from about 1 mg to about 5,000 mg per day.

30. (previously presented) The method of claim 29 wherein the therapeutically effective amount is from about 10 mg to about 2,500 mg per day.

31. (previously presented) The method of claim 30 wherein the therapeutically effective amount is from about 100 mg to about 1,200 mg per day.

32. (previously presented) The method of claim 29, wherein the enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered twice a day.

33-46. (canceled).